Suppression of adjuvant-induced disease (AID) by a novel analgesic-opioid agonist which also possesses antioxidant activity (neuroimmunomodulation).
A centrally acting analgesic-opioid agonist, PM, suppresses the primary inflammation and the secondary lesions of adjuvant-induced disease in rats. This compound also possesses antioxidant properties and inhibits the carrageenin-induced edema in mice. PM, therefore, is interfering to immune functions probably by binding to opioid receptors on lymphocytes and to inflammatory cells by its antioxidant activity.
Hadjipetrou-Kourounakis
L
L
Department of Biology, School of Science, Aristotelian University, Thessaloniki, Greece.
Rekka
E
E
Kourounakis
A
A
D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001169:Arthritis, Experimental / Q000276:immunology*; D005260:Female; D008054:Lipid Peroxides / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D009025:Morpholines / Q000494:pharmacology*; D015213:Neuroimmunomodulation; D051381:Rats; D011916:Rats, Inbred F344
D000700:Analgesics; D000975:Antioxidants; D008054:Lipid Peroxides; D009025:Morpholines; C059601:2-n-pentyloxy-2-phenyl-4-methylmorpholine